Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Surgical Treatment of Pulmonary Complications in Behçet's Syndrome.

Tuzun H, Seyahi E, Guzelant G, Oz B, Batur S, Demirhan O, Hamuryudan V.

Semin Thorac Cardiovasc Surg. 2018 Jul 19. pii: S1043-0679(18)30118-7. doi: 10.1053/j.semtcvs.2018.07.008. [Epub ahead of print]

PMID:
30031945
2.

Tapering tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective study.

Hacioglu A, Hatemi G, Esatoglu SN, Hamuryudan V.

Clin Exp Rheumatol. 2018 Apr 19. [Epub ahead of print] No abstract available.

PMID:
29745879
3.

Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies.

Ayan G, Esatoglu SN, Hatemi G, Ugurlu S, Seyahi E, Melikoglu M, Fresko I, Ozdogan H, Yurdakul S, Hamuryudan V.

Rheumatol Int. 2018 Apr;38(4):607-622. doi: 10.1007/s00296-018-3928-1. Epub 2018 Jan 10.

PMID:
29322343
4.

MiRNA and mRNA Profiling in Systemic Lupus Reveals a Novel Set of Cytokine - Related miRNAs and their Target Genes in Cases With and Without Renal Involvement.

Jafari Ghods F, Topal Sarikaya A, Arda N, Hamuryudan V.

Kidney Blood Press Res. 2017;42(6):1322-1337. doi: 10.1159/000485987. Epub 2017 Dec 15.

5.

Infliximab for uveitis of Behçet's syndrome: a trend for earlier initiation.

Guzelant G, Ucar D, Esatoglu SN, Hatemi G, Ozyazgan Y, Yurdakul S, Seyahi E, Yazici H, Hamuryudan V.

Clin Exp Rheumatol. 2017 Nov-Dec;35 Suppl 108(6):86-89. Epub 2017 Oct 24.

6.

One year in review 2017: Behçet's syndrome.

Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V.

Clin Exp Rheumatol. 2017 Nov-Dec;35 Suppl 108(6):3-15. Epub 2017 Sep 29. Review.

7.

Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever.

Ugurlu S, Hacioglu A, Adibnia Y, Hamuryudan V, Ozdogan H.

Orphanet J Rare Dis. 2017 May 30;12(1):105. doi: 10.1186/s13023-017-0642-0. Review.

8.

Shoulder in rheumatoid arthritis and its surgical options.

Aydin N, Aslan L, Lehtinen J, Hamuryudan V.

Curr Rheumatol Rev. 2016 Dec 1. [Epub ahead of print]

PMID:
27908254
9.

One year in review 2016: Behçet's syndrome.

Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V.

Clin Exp Rheumatol. 2016 Sep-Oct;34(6 Suppl 102):10-22. Epub 2016 Oct 13. Review.

10.

Bronchial artery enlargement may be the cause of recurrent haemoptysis in Behçet's syndrome patients with pulmonary artery involvement during follow-up.

Esatoglu SN, Seyahi E, Ugurlu S, Gulsen F, Akman C, Cantasdemir M, Numan F, Tuzun H, Melikoglu M, Yazici H, Hamuryudan V.

Clin Exp Rheumatol. 2016 Sep-Oct;34(6 Suppl 102):92-96. Epub 2016 Oct 11.

PMID:
27791952
11.

Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey.

Hamuryudan V, Direskeneli H, Ertenli I, Inanc M, Karaaslan Y, Oksel F, Ozbek S, Pay S, Terzioglu E, Balkan Tezer D, Hacibedel B, Akkoc N.

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1033-1037. Epub 2016 Sep 18.

PMID:
27749224
12.

Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy.

Ozguler Y, Hatemi G, Ugurlu S, Seyahi E, Melikoglu M, Borekci S, Atahan E, Ongen G, Hamuryudan V.

Rheumatol Int. 2016 Dec;36(12):1719-1725. Epub 2016 Oct 3.

PMID:
27699578
13.

Infliximab is a plausible alternative for neurologic complications of Behçet disease.

Zeydan B, Uygunoglu U, Saip S, Demirci ON, Seyahi E, Ugurlu S, Hamuryudan V, Siva A, Kantarci OH.

Neurol Neuroimmunol Neuroinflamm. 2016 Jul 8;3(5):e258. doi: 10.1212/NXI.0000000000000258. eCollection 2016 Oct.

14.

Behçet's syndrome: a critical digest of the 2014-2015 literature.

Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S3-14. Epub 2015 Oct 19. Review.

PMID:
26487500
15.

Pulmonary artery involvement in Behçet׳s syndrome: Effects of anti-Tnf treatment.

Hamuryudan V, Seyahi E, Ugurlu S, Melikoglu M, Hatemi G, Ozguler Y, Akman C, Tuzun H, Yurdakul S, Yazici H.

Semin Arthritis Rheum. 2015 Dec;45(3):369-73. doi: 10.1016/j.semarthrit.2015.06.008. Epub 2015 Jun 18.

PMID:
26190564
16.

Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-α treatment.

Borekci S, Atahan E, Demir Yilmaz D, Mazıcan N, Duman B, Ozguler Y, Musellim B, Hamuryudan V, Ongen G.

Respiration. 2015;90(3):191-8. doi: 10.1159/000434684. Epub 2015 Jun 30.

17.

Suicidal ideation among patients with Behçet's syndrome.

Saygin C, Uzunaslan D, Hatemi G, Hamuryudan V.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S30-5. Epub 2015 Mar 23.

PMID:
25797433
18.

Direct and indirect costs associated with ankylosing spondylitis and related disease activity scores in Turkey.

Akkoç N, Direskeneli H, Erdem H, Gül A, Kabasakal Y, Kiraz S, Balkan Tezer D, Hacıbedel B, Hamuryudan V.

Rheumatol Int. 2015 Sep;35(9):1473-8. doi: 10.1007/s00296-015-3236-y. Epub 2015 Mar 7.

19.

An outcome survey of 43 patients with Budd-Chiari syndrome due to Behçet's syndrome followed up at a single, dedicated center.

Seyahi E, Caglar E, Ugurlu S, Kantarci F, Hamuryudan V, Sonsuz A, Melikoglu M, Yurdakul S, Yazici H.

Semin Arthritis Rheum. 2015 Apr;44(5):602-609. doi: 10.1016/j.semarthrit.2014.10.014. Epub 2014 Nov 1.

PMID:
25476470
20.

Behçet's syndrome: a critical digest of the 2013-2014 literature.

Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4 Suppl 84):S112-22. Epub 2014 Sep 30. Review.

PMID:
25268667
21.

Self-criticism in Behçet's disease and other autoinflammatory conditions.

Yazici H, Talarico R, Hamuryudan V.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4 Suppl 84):S5-6. Epub 2014 Sep 29. No abstract available.

PMID:
25268659
22.

Impact of rheumatoid arthritis in Turkey: a questionnaire study.

Direskeneli H, Akkoç N, Bes C, Cakir N, Cefle A, Cobankara V, Dalkilic E, Dinc A, Ertenli I, Gul A, Hamuryudan V, Inanc M, Kalyoncu U, Karaaslan Y, Kasifoglu T, Keser G, Keskin G, Kisacik B, Kiraz S, Masatlioglu S, Onat AM, Ozbek S, Ozturk MA, Pamuk ON, Pay S, Pirildar T, Sayarlioglu M, Senel S, Senturk T, Tasan D, Terzioglu E, Yazici A, Yucel E.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4):477-83. Epub 2014 Jun 6.

PMID:
24960289
23.

Colchicine in Behçet syndrome: a longterm survey of patients in a controlled trial.

Hamuryudan V, Hatemi G, Tascilar K, Yurdakul S, Mat C, Ozyazgan Y, Seyahi E, Ugurlu S, Yazici H.

J Rheumatol. 2014 Apr;41(4):735-8. doi: 10.3899/jrheum.130847. Epub 2014 Feb 15.

PMID:
24532830
24.

Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Hatemi G, Merkel PA, Hamuryudan V, Boers M, Direskeneli H, Aydin SZ, Yazici H.

J Rheumatol. 2014 Mar;41(3):599-612. doi: 10.3899/jrheum.131249. Epub 2014 Feb 1. Review.

25.

Behçet's syndrome: a critical digest of the 2012-2013 literature.

Hatemi G, Seyahi E, Fresko I, Hamuryudan V.

Clin Exp Rheumatol. 2013 May-Jun;31(3 Suppl 77):108-17. Epub 2013 Sep 9. Review.

PMID:
24064024
26.

Behçet's syndrome: a critical digest of the recent literature.

Hatemi G, Seyahi E, Fresko I, Hamuryudan V.

Clin Exp Rheumatol. 2012 May-Jun;30(3 Suppl 72):S80-9. Epub 2012 Sep 25. Review.

PMID:
23009740
27.

Frequent oral ulceration during early disease may predict a severe disease course in males with Behçet's syndrome.

Hamuryudan V, Hatemi G, Sut N, Ugurlu S, Yurdakul S, Yazici H.

Clin Exp Rheumatol. 2012 May-Jun;30(3 Suppl 72):S32-4. Epub 2012 Oct 8.

PMID:
22935508
28.

The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey.

Malhan S, Pay S, Ataman S, Dalkilic E, Dinc A, Erken E, Ertenli I, Ertugrul E, Gogus F, Hamuryudan V, Inanc M, Karaarslan Y, Karadag O, Karakoc Y, Keskin G, Kisacik B, Kiraz S, Oksel F, Oksuz E, Pirildar T, Sari I, Soy M, Senturk T, Taylan A.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2):202-7. Epub 2012 Apr 13.

PMID:
22546069
29.

Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients.

Seyahi E, Melikoglu M, Akman C, Hamuryudan V, Ozer H, Hatemi G, Yurdakul S, Tuzun H, Oz B, Yazici H.

Medicine (Baltimore). 2012 Jan;91(1):35-48. doi: 10.1097/MD.0b013e318242ff37.

30.

Acute phase response and oxidative stress status in familial Mediterranean fever (FMF).

Guzel S, Andican G, Seven A, Aslan M, Bolayirli M, Guzel EC, Hamuryudan V.

Mod Rheumatol. 2012 Jun;22(3):431-7. doi: 10.1007/s10165-011-0517-5. Epub 2011 Sep 23.

PMID:
21947799
31.

Management and prognosis of nonpulmonary large arterial disease in patients with Behçet disease.

Tuzun H, Seyahi E, Arslan C, Hamuryudan V, Besirli K, Yazici H.

J Vasc Surg. 2012 Jan;55(1):157-63. doi: 10.1016/j.jvs.2011.07.049. Epub 2011 Sep 23.

32.

The estimated pulmonary artery pressure can be elevated in Behçet's syndrome.

Seyahi E, Baskurt M, Melikoglu M, Akman C, Olgun DC, Simsek E, Hamuryudan V, Kucukoglu S, Yazici H.

Respir Med. 2011 Nov;105(11):1739-47. doi: 10.1016/j.rmed.2011.07.022. Epub 2011 Sep 8.

33.

Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire.

Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, Da Silva JP, de Wit M, Dougados M, Durez P, Emery P, Fonseca JE, Gibofsky A, Gomez-Reino J, Graninger W, Hamuryudan V, Jannaut Peña MJ, Kalden J, Kvien TK, Laurindo I, Martin-Mola E, Montecucco C, Santos Moreno P, Pavelka K, Poor G, Cardiel MH, Stanislawska-Biernat E, Takeuchi T, van der Heijde D; Treat to Target Taskforce.

Ann Rheum Dis. 2011 Nov;70(11):1999-2002. doi: 10.1136/ard.2011.154179. Epub 2011 Jul 29.

34.

Dissemination and evaluation of the 3E initiative recommendations for use of methotrexate in rheumatic disorders: results of a study among 2233 rheumatologists.

Gossec L, Bijlsma JW, Bombardier C, Canhão H, Devlin J, Edwards CJ, Hamuryudan V, Kvien TK, Leeb BF, Martín-Mola EM, Mielants H, Müller-Ladner U, Ostergaard M, Pereira IA, Ramos-Remus C, Zochling J, Dougados M.

Ann Rheum Dis. 2011 Feb;70(2):388-9. doi: 10.1136/ard.2010.128652. Epub 2010 May 14. No abstract available.

PMID:
20472594
35.

Analyses of functional IL10 and TNF-α genotypes in Behçet's syndrome.

Ateş O, Dalyan L, Hatemi G, Hamuryudan V, Topal-Sarıkaya A.

Mol Biol Rep. 2010 Oct;37(7):3637-41. doi: 10.1007/s11033-010-0015-4. Epub 2010 Feb 27.

PMID:
20191386
36.

Interferon therapy in rheumatic diseases: state-of-the-art 2010.

Kötter I, Hamuryudan V, Oztürk ZE, Yazici H.

Curr Opin Rheumatol. 2010 May;22(3):278-83. doi: 10.1097/BOR.0b013e3283368099. Review.

PMID:
20061957
37.

Prognosis of Behcet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial.

Hamuryudan V, Hatemi G, Tascilar K, Sut N, Ozyazgan Y, Seyahi E, Mat C, Yurdakul S, Yazici H.

Rheumatology (Oxford). 2010 Jan;49(1):173-7. doi: 10.1093/rheumatology/kep350.

PMID:
19995858
38.

NRAMP1 (SLC11A1) gene polymorphisms that correlate with autoimmune versus infectious disease susceptibility in tuberculosis and rheumatoid arthritis.

Ates O, Dalyan L, Müsellim B, Hatemi G, Türker H, Ongen G, Hamuryudan V, Topal-Sarikaya A.

Int J Immunogenet. 2009 Feb;36(1):15-9. doi: 10.1111/j.1744-313X.2008.00814.x. Epub 2008 Nov 25.

PMID:
19055603
39.

Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative.

Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, Bombardier C, Carmona L, van der Heijde D, Bijlsma JW, Boumpas DT, Canhao H, Edwards CJ, Hamuryudan V, Kvien TK, Leeb BF, Martín-Mola EM, Mielants H, Müller-Ladner U, Murphy G, Østergaard M, Pereira IA, Ramos-Remus C, Valentini G, Zochling J, Dougados M.

Ann Rheum Dis. 2009 Jul;68(7):1086-93. doi: 10.1136/ard.2008.094474. Epub 2008 Nov 25.

40.

Serum and synovial fluid leptin levels and markers of inflammation in rheumatoid arthritis.

Seven A, Güzel S, Aslan M, Hamuryudan V.

Rheumatol Int. 2009 May;29(7):743-7. doi: 10.1007/s00296-008-0764-8. Epub 2008 Nov 14.

PMID:
19009296
41.

Genetic susceptibility to Behçet's syndrome is associated with NRAMP1 (SLC11A1) polymorphism in Turkish patients.

Ateş O, Dalyan L, Hatemi G, Hamuryudan V, Topal-Sarikaya A.

Rheumatol Int. 2009 May;29(7):787-91. doi: 10.1007/s00296-008-0763-9. Epub 2008 Nov 8.

PMID:
18998137
42.

Comment on "Cardiac Behçet disease presenting as aortic valvulitis/aortitis or right heart inflammatory mass: a clinicopathologic study of 12 cases".

Hamuryudan V, Seyahi E, Yazici H.

Am J Surg Pathol. 2008 Dec;32(12):1914-5; author reply 1915-6. doi: 10.1097/PAS.0b013e31818479e4. No abstract available.

PMID:
18824894
43.

Tumor necrosis factor-alpha and interleukin-10 gene promoter polymorphisms in Turkish rheumatoid arthritis patients.

Ates O, Hatemi G, Hamuryudan V, Topal-Sarikaya A.

Clin Rheumatol. 2008 Oct;27(10):1243-8. doi: 10.1007/s10067-008-0893-1. Epub 2008 Apr 22.

PMID:
18427872
44.

Lipid, protein, DNA oxidation and antioxidant status in rheumatoid arthritis.

Seven A, Güzel S, Aslan M, Hamuryudan V.

Clin Biochem. 2008 May;41(7-8):538-43. doi: 10.1016/j.clinbiochem.2008.01.029. Epub 2008 Feb 15.

PMID:
18313405
45.

Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists.

Sidiropoulos PI, Hatemi G, Song IH, Avouac J, Collantes E, Hamuryudan V, Herold M, Kvien TK, Mielants H, Mendoza JM, Olivieri I, Østergaard M, Schachna L, Sieper J, Boumpas DT, Dougados M.

Rheumatology (Oxford). 2008 Mar;47(3):355-61. doi: 10.1093/rheumatology/kem348. Review.

PMID:
18276738
46.

Atherosclerosis in Behçet's Syndrome.

Seyahi E, Ugurlu S, Cumali R, Balci H, Ozdemir O, Melikoglu M, Hatemi G, Fresko I, Hamuryudan V, Yurdakul S, Yazici H.

Semin Arthritis Rheum. 2008 Aug;38(1):1-12. doi: 10.1016/j.semarthrit.2007.09.009. Epub 2008 Jan 25.

PMID:
18221989
47.

Thalidomide has both anti-inflammatory and regulatory effects in Behcet's disease.

Direskeneli H, Ergun T, Yavuz S, Hamuryudan V, Eksioglu-Demiralp E.

Clin Rheumatol. 2008 Mar;27(3):373-5. Epub 2007 Nov 23.

PMID:
18034203
48.

Infliximab in the treatment of hepatic vein thrombosis (Budd-Chiari syndrome) in three patients with Behcet's syndrome.

Seyahi E, Hamuryudan V, Hatemi G, Melikoglu M, Celik S, Fresko I, Yurdakul S, Yazici H.

Rheumatology (Oxford). 2007 Jul;46(7):1213-4. Epub 2007 May 3. No abstract available.

PMID:
17478465
49.

Anti-Saccharomyces cerevisiae antibodies (ASCA) in Behçet's syndrome.

Fresko I, Ugurlu S, Ozbakir F, Celik A, Yurdakul S, Hamuryudan V, Yazici H.

Clin Exp Rheumatol. 2005 Jul-Aug;23(4 Suppl 38):S67-70.

PMID:
16273768
50.

Fibrinolytic activity and d-dimer levels in Behçet's syndrome.

Yurdakul S, Hekim N, Soysal T, Fresko I, Bavunoglu I, Ozbakir F, Tabak F, Melikoglu M, Hamuryudan V, Yazici H.

Clin Exp Rheumatol. 2005 Jul-Aug;23(4 Suppl 38):S53-8.

PMID:
16273765

Supplemental Content

Loading ...
Support Center